about
Circulating mitochondrial biomarkers for drug-induced liver injuryMicroRNAs in Drug-induced Liver InjuryDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsMethodology to assess clinical liver safety dataPathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significanceLTMap: a web server for assessing the potential liver toxicity by genome-wide transcriptional expression data.Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.Limited Link between Oxidative Stress and Ochratoxin A-Induced Renal Injury in an Acute Toxicity Rat Model.In silico models for drug-induced liver injury--current status.A decade of toxicogenomic research and its contribution to toxicological science.Latest advances in predicting DILI in human subjects: focus on biomarkers.Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury.MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans.Analysis of cis-Regulatory Elements in Gene Co-expression Networks in Cancer.The pathogenesis of drug-induced liver injury.Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice.Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity.Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status.
P2860
Q26778353-6C87BE29-E676-4379-ADA9-C3E4601F9B9BQ26781801-94AAF4D5-5941-4AD9-8067-6585A910EC70Q26781892-704A107F-02AB-40AC-8653-376CC08B4006Q26853437-C853799F-B1BB-41FA-9D2B-321AFEA6B370Q27690772-711DCA62-028C-46EC-B3BD-102990251A3CQ28478443-F462363D-0404-408E-BA3F-2C2CBBF287C3Q28538041-C5812678-44F0-4975-9CAA-7BCFD17A64BAQ30666142-76E7BFEB-75F7-4A60-A077-4166287D5C8FQ30838395-22B83F71-D3DB-4543-B2C9-5A0959843EBFQ34169945-905EF0BD-1301-406A-8FF3-8E0532DE2EE0Q36267296-A7AD1FD7-9802-421B-9C29-AB4574DE94B8Q37543631-87E91259-0277-4036-8D2E-27EF70900E64Q37976120-DC0C592C-AAF6-4E5B-B9C3-96AF7DF948CFQ38025961-288D2DA1-2AAA-4AE9-A291-92CF42694EC5Q38045377-1BB557CF-98DA-4939-8CBD-C3991E95D5ACQ38095111-365A70E1-C2A8-4721-ACDF-BF5EBF353CC8Q38201510-39ECAF88-DAAB-4678-8F70-FCD8B9ACCD6BQ38604264-01268621-E737-4267-B9B9-667B0A7D7A6AQ38849978-EF2B35B1-6110-46DE-B306-D2DBF1A35B58Q39234138-D853B0D8-8415-4D23-B45D-284BC4C18CDAQ41513917-758B2C9D-0FE9-486F-A59A-B8DC598F1DE7Q41867355-6AADE400-0D57-4ECB-9A79-1F310DFFBCFDQ42723585-44EC502B-609E-4E96-9DF1-D0D2D1144628Q47781069-348BC2B1-5570-474E-B4B6-052EB4DCFD16
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers for drug-induced liver injury.
@en
Biomarkers for drug-induced liver injury.
@nl
type
label
Biomarkers for drug-induced liver injury.
@en
Biomarkers for drug-induced liver injury.
@nl
prefLabel
Biomarkers for drug-induced liver injury.
@en
Biomarkers for drug-induced liver injury.
@nl
P2093
P2860
P356
P1476
Biomarkers for drug-induced liver injury.
@en
P2093
Huixiao Hong
John Senior
P2860
P304
P356
10.1586/EGH.10.8
P50
P577
2010-04-01T00:00:00Z